文献速递精神分裂症与精神病性障碍老年精神会诊联络精神医学

第二代抗精神病药与短期躯体严重不良事件:系统综述与Meta分析

Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2019-07-15

BACKGROUND: Antipsychotic drugs might cause acutely occurring, serious side-effects and thus contribute to the increased physical morbidity and mortality observed in patients with severe mental health disorders.…

核心结论

  • 第二代抗精神病药可导致短期躯体严重不良事件,该效应主要由老年患者结果驱动,临床应警惕其潜在毒性。

主要发现

  • 88%的试验持续时间≤13周(中位6周,IQR 4–9),30项(5%)为高偏倚风险、358项(60%)为中等、209项(35%)为低偏倚风险。
  • 主要结局分析的τ²均为零,贝叶斯敏感性分析结果相似。

临床怎么用

  • 临床医生应认识到抗精神病药具有潜在毒性,尤其对与老年人群共享风险因素的患者需加强监测。
  • 处方第二代抗精神病药时应权衡短期躯体严重不良事件风险,对65岁以上患者更应谨慎。

局限性

  • 大多数试验持续时间较短(中位6周),可能低估长期风险。
  • 仅纳入安慰剂对照试验,排除了中国大陆研究及持续时间不足1天的心理学研究。
  • 儿童青少年亚组证据不确定性较大(95%CI宽且跨1)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antipsychotic drugs might cause acutely occurring, serious side-effects and thus contribute to the increased physical morbidity and mortality observed in patients with severe mental health disorders. We examined this hypothesis by doing a meta-analysis of International Conference on Harmonisation-Good Clinical Practice-defined serious adverse events occurring in placebo-controlled trials of antipsychotics. METHODS: For this systematic review and meta-analysis, we included randomised controlled trials (RCTs) comparing second-generation antipsychotics with placebo. We searched MEDLINE, Embase, Cochrane CENTRAL, BIOSIS, PsycINFO, PubMed, ClinicalTrials.gov, and WHO International Clinical Trials Registry Platform for trials published in any language from database inception up until Jan 27, 2017. Trials were included without limitations in population (diagnostic category, age, sex, ethnicity), dosing regimen, blinding status, duration, or publication year. Only psychological studies lasting less than 1 day and trials done in mainland China were excluded. We contacted pharmaceutical companies, drug regulatory authorities, and study investigators for additional data. The primary outcome was the number of patients with at least one somatic serious adverse event. We estimated minimum and maximum numbers of patients with the outcome in each study group and synthesised the results with odds ratios (ORs) in a common-effects meta-analysis. This study is registered with PROSPERO, number CRD42016033930. FINDINGS: We identified 597 RCTs, comprising 108 664 participants, that met the inclusion criteria. 314 trials (67 642 participants) with details on individual serious adverse events available constituted the main dataset for meta-analysis. 88% of these were 13 weeks (approximately 3 months) or shorter in duration (median 6 weeks, IQR 4-9). At least one somatic serious adverse event occurred in 698 (1·63%) to 862 (2·02%) of 42 600 patients on antipsychotics, and in 343 (1·37%) to 419 (1·67%) of 25 042 patients on placebo. The odds ratios (ORs) were 1·24 (95% CI 1·08-1·42) and 1·24 (1·10-1·41) based on the minimum and maximum estimate, respectively. In predefined subgroup analyses we found evidence suggesting a larger effect in older patients (>65 years; OR 1·56, 95% CI 1·22-1·98; 1·58, 1·25-1·99) as compared with adults (18-65 years; 1·09, 0·91-1·29; 1·10, 0·95-1·28); likewise in children or adolescents (<18 years) although the evidence was more uncertain (1·49, 0·81-2·75; 1·54, 0·85-2·77). Of 597 included RCTs, 30 (5%), 358 (60%), and 209 (35%) were rated at high, moderate, or low risk of bias, respectively. τ2 was zero for both analyses of the primary outcome (minimum estimate, maximum estimate). A Bayesian sensitivity analysis using external information on heterogeneity gave similar results. INTERPRETATION: We found evidence that antipsychotics cause short-term somatic serious adverse events on top of somatic serious adverse events occurring independent of treatment. This effect appears to be mainly driven by results in older patients. Hence, clinicians should be aware that antipsychotics are potentially toxic, particularly when treating patients sharing risk factors with the older population. FUNDING: German Ministry of Education and Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Schneider-Thoma J, Efthimiou O, Bighelli I, et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry. 2019. PMID: 31320283. doi:10.1016/S2215-0366(19)30223-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。